-
B.Riley Starts Heartbeam Inc. (BEAT) at Buy
-
D. Boral Capital Starts Heartbeam Inc. (BEAT) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Heartbeam Inc. (BEAT)
-
Benchmark Downgrades Heartbeam Inc. (BEAT) to Speculative Buy
-
HeartBeam, Inc (BEAT) Misses Q4 EPS by 46c
-
HeartBeam partners with Mount Sinai on AI cardiac monitoring development
-
HeartBeam, Inc (BEAT) files $100M mixed shelf
-
Benchmark Upgrades Heartbeam Inc. (BEAT) to Buy
-
Heartbeam Inc. (BEAT) PT Raised to $5.50 at H.C. Wainwright
-
HeartBeam gets FDA clearance for cable-free 12-lead ECG device
-
H.C. Wainwright Starts Heartbeam Inc. (BEAT) at Buy
-
HeartBeam receives FDA rejection, pursues multiple paths for approval
-
HeartBeam, Inc (BEAT) Misses Q3 EPS by 7c
-
Roth/MKM Starts Heartbeam Inc. (BEAT) at Buy
-
HeartBeam AI shows comparable accuracy to standard ECGs for arrhythmias
-
Benchmark Reiterates Speculative Buy Rating on Heartbeam Inc. (BEAT)
-
HeartBeam, Inc (BEAT) Tops Q2 EPS by 1c
-
Benchmark Reiterates Speculative Buy Rating on Heartbeam Inc. (BEAT)
-
HeartBeam, Inc (BEAT) Misses Q1 EPS by 2c
-
HeartBeam, Inc (BEAT) Appoints CEO Robert Eno to its Board
-
HeartBeam, Inc (BEAT) Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology
-
HeartBeam, Inc (BEAT) partners with AccurKardia on cardiac monitoring
-
Benchmark Reiterates Speculative Buy Rating on Heartbeam Inc. (BEAT)
-
HeartBeam, Inc (BEAT) Reports FY Loss of $0.73
-
HeartBeam, Inc (BEAT) Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock
-
HeartBeam, Inc (BEAT) Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
-
HeartBeam, Inc (BEAT) Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
-
HeartBeam (BEAT) Announces Positive Data from Two Studies
-
HeartBeam, Inc (BEAT) Misses Q3 EPS by 4c
-
HeartBeam, Inc (BEAT) Appoints Robert Eno as CEO
-
HeartBeam, Inc (BEAT) Appoints Lance Myers as Chief AI Scientist
-
HeartBeam (BEAT) Appoints Timothy Cruickshank as CFO
-
Benchmark Reiterates Speculative Buy Rating on Heartbeam Inc. (BEAT)
-
HeartBeam, Inc (BEAT) Misses Q2 EPS by 2c

